MedTrace Logo

Efficacy and Safety Study of SLC022 in Treating Pain Associated With Post Herpetic Neuralgia

NCT00813826 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 204

Last updated 2009-07-30

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of SLC022 in treating pain associated with post-herpetic neuralgia (PHN) in recently diagnosed patients.

Conditions

  • Postherpetic Neuralgia

Interventions

DRUG

SLC022

SLC022 150 mg capsule, 900mg daily dose

DRUG

Placebo

Placebo capsule, TID

Sponsors & Collaborators

  • Solace Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Kevin Pojasek, PhD · Solace Pharmaceuticals Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2009-10-31
Completion
2009-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00813826 on ClinicalTrials.gov